TRTimothy Richard Rebbeck

Timothy Richard Rebbeck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy Richard Rebbeck has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Determinants of prostate-specific antigen levels in African men

    by Eunsoo Cho, Ilir Agalliu, Thomas Rohan, Alfred I Neugut, Shakuntala Baichoo, Ianne Holanda Lauder, Akkshaya Rajesh, Hafees Ajibola, Oseremen Aisuodionoe-Shadrach, Pedro W Fernandez, et al.

    Background: Prostate-specific antigen (PSA) is widely used for screening and diagnosis of prostate cancer. Variation in PSA levels is influenced by age, genetics, and other factors, yet this variation has not been well characterized in African men. Methods: We used data on serum PSA extracted from medical records from prostate cancer cases and controls collected as part of the Men of African Descent and Carcinoma of the Prostate (MADCaP) network. We evaluate the association of PSA levels with country of origin, age, body mass index (BMI), and polygenic risk score. Results: The median PSA levels were 41.8 (0.2-9696) ng/mL in 1907 prostate cancer cases and 1.235 (0.01-9.72) ng/mL in 902 controls. Higher PSA levels were associated with increasing age, lower BMI, higher Gleason score, and more advanced tumor stage in cases, explaining approximately 35% of variation in log-transformed PSA levels. In controls, 4.8% of PSA variation was explained by age. Conclusion: Our data in African men are consistent with non-African studies that report PSA levels increase with age, inversely with BMI (suggesting a PSA dilution effect or reverse causation), and with more aggressive disease in cases. These data may be used to help understand PSA distributions and in the future may guide screening practices in African men.

  • Open Access

    The emerging landscape of cancer genomics in Africa: a narrative review of progress, initiatives, and the path forward

    by Yosr Hamdi, Prisca Adejumo, Mohamed Zahir Alimohamed, Collet Dandara, Temidayo Fadelu, Wijden Mafoudh, Achille Manirakiza, Nicola Mulder, Rokhaya Ndiaye, Folakemi T. Odedina, et al.

  • Some answers, more questions for multi-cancer early detection tests

    by Catherine R. Marinac, Timothy R. Rebbeck, Elizabeth K. O’DOnnell


  • Open Access

    Supplementary Mats and Methods from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

  • Open Access

    A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program

    by Anissa V. Bailey, Stephen Frochen, Lorna Kwan, Mehrnaz Siavoshi, Candace L. Haroldsen, Jeremy B. Shelton, Brent Rose, Kara N. Maxwell, Nicholas G. Nickols, Kosj Yamoah, et al.

    Background: Men seeking care in the Veterans Health Administration (VHA) may have higher prostate cancer (PCa) incidence, metastases, and mortality (PCSM) relative to the general US population due to military exposures and increased access to care. We compared rates in both populations using contemporary databases. Methods: Annual PCa incidence, metastasis, and PCSM rates between 2008 and 2022 were obtained from the Surveillance, Epidemiology, and End Results (SEER) Program and calculated from the VA Multi-OMICS Analysis Platform for Prostate Cancer (VA-MAPP) database. Age-adjusted rates per 100,000 were standardized to the veteran’s age distribution and stratified by race/ethnicity and age group (<50, 50-64, 65+ years). Joinpoint regression was used to evaluate trends in rates following changes in United States Preventive Services Task Force (USPSTF) screening recommendations. Results: PCa incidence and PCSM rates were higher in the VHA vs SEER (RR2018-2022: 3.34, 95% CI: 3.32-3.36). However, metastatic rates were lower in the VHA compared to SEER (RR2018-2022: 0.69, 95% CI: 0.67-0.71). PCa incidence declined in the VHA (APC2008-2011: 7.3, 95% CI: 5.0-9.6) and SEER (APC2008-2011: 3.2, 95% CI: 0.7-5.6) prior to USPSTF 2012 guidelines, but metastatic rates increased in the VHA (APC2012-2017: 4.6, 95% CI: 2.1-7.1) and SEER (APC2012-2017: 3.3, 95% CI: 1.5-5.3), followed by general flattening of incidence, metastasis, and PCSM in both groups. Conclusions: Higher PCa incidence and PCSM was observed in VHA compared to SEER, but not metastasis. Impact: Increased access to care could explain higher incidence but more favorable metastatic presentation in VHA compared to SEER.

  • Open Access

    Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.

    by Martin W Schoen, Jiannong Li, Sihang Zeng, Heena Desai, Ryan Hausler, Candace L Haroldsen, Lukas Owens, Luca F Valle, Ruth B Etzoni, Timothy R Rebbeck, et al.

    Tumor comprehensive genomic profiling (CGP) has revolutionized cancer care and identifies patients for biomarker-specific therapy. In metastatic hormone-sensitive prostate cancer (mHSPC), although individual genes are prognostic, no comprehensive genomic classification exists using CGP that accounts for combinations of alterations to inform prognosis. We developed a DNA-based CGP classification that is prognostic for overall survival (OS) and could inform treatment. This was a retrospective cross-sectional study using multivariable models to develop a clinicogenomic prognostic risk classification in US veterans with synchronous mHSPC. The primary outcome was OS from time of metastasis. A total of 7,201 veterans with metastatic prostate cancer and CGP were identified. There were 2,484 veterans (median [IQR] age, 72 [67-77] years) with synchronous mHSPC and tissue CGP, which were divided into training and testing data sets. Sixteen genes associated with survival were identified, and favorable, intermediate, and unfavorable genomic prognostication groups were created based on the mortality risk to generate the Somatic Tumor Risk Assessment for OS-Prostate (STRATOS-P) classification. In a multivariable model, classification into intermediate and unfavorable groups was associated with increased mortality relative to the favorable group (adjusted hazard ratio [aHR], 1.54 [95% CI, 1.33 to 1.78]; aHR, 2.37 [95% CI, 1.97 to 2.485], respectively), demonstrating an average AUC of 0.83. In an external, nonveterans validation cohort, intermediate and unfavorable classifications were associated with increased mortality (aHR, 2.45 [95% CI, 1.87 to 3.21]; aHR, 4.37 [95% CI, 3.06 to 6.22], respectively) with an AUC of 0.79. The intermediate and unfavorable genomic prognostication groups were also associated with increased mortality across multiple disease states including synchronous and metachronous diagnoses, castration resistance, and analyte type. In metastatic prostate cancer, tumor DNA genomic alterations are prognostic for OS. The STRATOS-P classification is a validated prognostic tool that has the potential to guide decision making in mHSPC.

  • Open Access

    Supplementary Mats and Methods from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

  • Open Access

    Data from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

    Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

  • A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study

    by Tia L. Kauffman, Elizabeth K. O’DOnnell, Catherine R. Marinac, Ana Babic, Kareem Adams, Jenna B. Beckwith, Tara A. Berman, Kristen D. Brantley, Dipanjan Chowdhury, Brian D. Crompton, et al.

    Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.

  • The Rising Burden of Early-Onset Cancer: Challenges and Opportunities

    by Andrea Cercek, Daniel J. Zabransky, Gianluca Mauri, Elizabeth M. Jaffee, Alberto Bardelli, Timothy R. Rebbeck

    Summary: Early-onset cancers are increasing globally, yet traditional research frameworks have yet to inform the epidemiologic and biological underpinnings of this trend. This perspective summarizes the current state of knowledge and prospects for a research agenda spanning epidemiology, exposure science, mechanistic studies, and federated infrastructures to address this emerging challenge.